Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)

Arch Endocrinol Metab. 2024 Nov 25:68:e240422. doi: 10.20945/2359-4292-2024-0422. eCollection 2024.

Abstract

Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.

Keywords: Obesity; antiobesity drugs; weight loss.

Publication types

  • Review

MeSH terms

  • Adult
  • Anti-Obesity Agents* / therapeutic use
  • Brazil
  • Comorbidity*
  • Endocrinology / standards
  • Humans
  • Metabolic Syndrome* / drug therapy
  • Obesity* / drug therapy
  • Societies, Medical*

Substances

  • Anti-Obesity Agents